This database contains 144 studies, archived under the term: "prevention & control"
Click here to filter this large number of results.
Feasibility, safety and preliminary evidence of the effectiveness of a home-based exercise programme for older people with Alzheimer’s disease: a pilot randomized controlled trial
Suttanon, P.,
Hill, K. D.,
Said, C. M.,
Williams, S. B.,
Byrne, K. N.,
LoGiudice, D.,
Lautenschlager, N. T.,
Dodd, K. J.
Objective: To evaluate the feasibility and safety of a home-based exercise programme for people with Alzheimer’s disease, and to provide preliminary evidence of programme effectiveness in improving balance and mobility and reducing falls risk.; Design: A randomized controlled trial.; Setting: Community.; Participants: Forty people with mild to moderate Alzheimer’s disease (mean age 81.9, SD 5.72; […]
Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial
Sullivan, Mark D.,
Katon, Wayne J.,
Lovato, Laura C.,
Miller, Michael E.,
Murray, Anne M.,
Horowitz, Karen R.,
Bryan, R. Nick,
Gerstein, Hertzel C.,
Marcovina, Santica,
Akpunonu, Basil E.,
Johnson, Janice,
Yale, Jean Francois,
Williamson, Jeff,
Launer, Lenore J.
Importance: Depression has been identified as a risk factor for dementia among patients with type 2 diabetes mellitus but the cognitive domains and patient groups most affected have not been identified.; Objective: To determine whether comorbid depression in patients with type 2 diabetes accelerates cognitive decline.; Design: A 40-month cohort study of participants in the […]
Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the Réseau sur la Maladie d’Alzheimer Français cohort
Soto, Maria E.,
Abellan van Kan, Gabor,
Nourhashemi, Fati,
Gillette-Guyonnet, Sophie,
Cesari, Matteo,
Cantet, Christelle,
Rolland, Yves,
Vellas, Bruno
Objectives: To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer’s disease (AD) than in those using other hypertensive or no drugs.; Design: Four-year prospective multicenter cohort study with a biannual assessment.; Setting: Memory clinics from 16 university hospitals in France.; Participants: Community-dwelling older adults with […]
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study
Sink, Kaycee M.,
Leng, Xiaoyan,
Williamson, Jeff,
Kritchevsky, Stephen B.,
Yaffe, Kristine,
Kuller, Lewis,
Yasar, Sevil,
Atkinson, Hal,
Robbins, Mike,
Psaty, Bruce,
Goff, David C.
Background: Hypertension (HTN) is a risk factor for dementia, and animal studies suggest that centrally active angiotensin-converting enzyme (ACE) inhibitors (those that cross the blood-brain barrier) may protect against dementia beyond HTN control.; Methods: Participants in the Cardiovascular Health Study Cognition Substudy with treated HTN and no diagnosis of congestive heart failure (n = 1054; […]
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
Simioni, Samanta,
Cavassini, Matthias,
Annoni, Jean-Marie,
Rimbault Abraham, Aline,
Bourquin, Isabelle,
Schiffer, Véronique,
Calmy, Alexandra,
Chave, Jean-Philippe,
Giacobini, Ezio,
Hirschel, Bernard,
Du Pasquier, Renaud A.
Objective: To determine the prevalence of cognitive complaints and HIV-associated neurocognitive disorders (HANDs) in a cohort of aviremic HIV-positive patients. To evaluate the relevance of the HIV dementia scale to detect HANDs.; Design: Assessment of HANDs with neuropsychological tests.; Methods: Two hundred HIV-infected patients with undetectable HIV-1 RNA concentrations in the plasma, no history of […]
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D.,
Doros, G.,
Gevorkian, S.,
Malarick, K.,
Reuter, M.,
Coutu, J.-P.,
Triggs, T. D.,
Wilkens, P. J.,
Matson, W.,
Salat, D. H.,
Hersch, S. M.
Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers.; Methods: Sixty-four eligible consenting participants were randomly allocated (1:1) to 15 g twice daily of creatine monohydrate or placebo for a 6-month double-blind […]
Malnutrition in community-dwelling adults with dementia (NutriAlz Trial)
Objectives: The objective of this study is to assess the nutritional status, measured by the MNA, in community-dwelling elderly individuals with dementia and to identify clinical risk factors for nutritional risk or malnutrition.; Design: Cross-sectional analysis of a cluster randomized clinical trial (Nutrialz).; Setting: Community-dwelling individuals attending dementia clinics.; Participants: 940 individuals.; Measurements: The clinical […]
Screening by telephone in the Alzheimer’s disease anti-inflammatory prevention trial
Reckess, Gila Z.,
Brandt, Jason,
Luis, Cheryl A.,
Zandi, Peter,
Martin, Barbara,
Breitner, John C. S.
Compared with in-person assessment methods, telephone screening for dementia and other cognitive syndromes may improve efficiency of large population studies or prevention trials. We used data from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial to compare performance of a four-test Telephone Assessment Battery (TAB) that included the Telephone Interview for Cognitive Status (TICS) to that of […]